A mathematician has disclosed how he managed to win the lottery an astonishing 14 times. The 91-year-old utilised mathematical probability and calculated strategies to consistently claim jackpots over ...

SPRING, Texas, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical company headquartered in Spring, Texas; announced today presentation at the San Antonio Breast ...

Trial demonstrated treatment with fixed duration EPKINLY plus rituximab and lenalidomide (EPKINLY+ R 2) resulted in statistically significant and clinically meaningful reduction in the risk of disease ...

Genmab A/S (Nasdaq: GMAB) today announced primary data from the pivotal Phase 3 EPCORE® FL-1 study evaluating fixed duration EPKINLY® (epcoritamab-bysp) in combination with rituximab and lenalidomide ...

SOLSTICE trial data demonstrate that 66% of chronic hepatitis delta participants receiving a monthly dose of tobevibart and elebsiran achieved undetectable HDV RNA at Week 48 Combination ...

Save hours on data entry and formula writing with my game-changing AI tips. From the laptops on your desk to satellites in space and AI that seems to be everywhere, I cover many topics at PCMag. I've ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

A new report today from analyst Jeff Pu has details on what to expect from next year’s highly-anticipated iPhone 18 Fold. According to Pu, Apple will use a combination of titanium and aluminum for the ...

“Dooring,” the common term for bike/car accidents, statistically causes the majority of harmful biking incidents. In Aspen, with a growing number of bike lanes adjacent to parallel parking, the number ...

Microsoft has launched AI agents for Word, Excel, and PowerPoint. The agents are available for business and individual subscribers. Now accessible on the web, the agents will expand to the desktop.

FOOTHILL RANCH, Calif.--(BUSINESS WIRE)--TAE Life Sciences (TLS) today announced preclinical results from its collaboration with Kyoto University, demonstrating that its next-generation boron drugs, ...

Clinical data demonstrate the combination of tarlatamab with anti-PD-L1 therapy as first-line maintenance has an acceptable safety profile and resulted in unprecedented overall survival in patients ...